Sheila Mariano
Internal Medicine · Jonesboro, LANPI 1104896919
Payments from drug & device makers
Across 99 payments — averaging $18.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$250
- Lilly USA, LLC$240
- Amgen$214
- Novo Nordisk$177
- Merck$172
- AbbVie$110
- plus $712 from 13 others
What the payments were for
- Food & beverage$1,875100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $250 |
| Lilly USA, LLC | 13 | $240 |
| Amgen | 11 | $214 |
| Novo Nordisk | 11 | $177 |
| Merck | 11 | $172 |
| AbbVie | 5 | $110 |
| Abbott | 5 | $108 |
| Boehringer Ingelheim | 6 | $96 |
| Bayer | 4 | $87 |
| Alpha Cognition USA, Inc. | 1 | $87 |
| Novartis | 4 | $78 |
| Pharmacyclics LLC, An Abbvie Company | 3 | $77 |
| Johnson & Johnson | 4 | $67 |
| Avanir Pharmaceuticals, Inc. | 2 | $29 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Insulet Corporation | 1 | $19 |
| Sanofi-aventis U.S. LLC | 1 | $16 |
| Pfizer | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $14 |
How this compares
$1,875 in reported general payments places this provider in the 70th percentile of 1,528 internal medicine providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 79 | $96,408 |
| FarxigaDapagliflozin Propanediol | 115 | $84,481 |
| MounjaroTirzepatide | 57 | $83,057 |
| JardianceEmpagliflozin | 71 | $72,693 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 74 | $54,508 |
| EliquisApixaban | 47 | $42,569 |
| JanuviaSitagliptin Phosphate | 42 | $32,625 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 42 | $28,588 |
| GlyxambiEmpagliflozin/Linagliptin | 18 | $26,092 |
| ProliaDenosumab | 13 | $21,611 |
| Repatha SureclickEvolocumab | 28 | $15,677 |
| MyrbetriqMirabegron | 17 | $15,468 |
| TradjentaLinagliptin | 14 | $15,179 |
| LinzessLinaclotide | 16 | $12,801 |
| Tresiba Flextouch U-200Insulin Degludec | 20 | $10,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr, Glyxambi, Tradjenta | $96 | $142,552145 claims |
| Novo NordiskOzempic | $177 | $96,40879 claims |
| AstraZenecaFarxiga | $250 | $84,481115 claims |
| Lilly USA, LLCMounjaro | $240 | $83,05757 claims |
| PfizerEliquis, Dilantin | $14 | $44,83859 claims |
| MerckJanuvia | $172 | $32,62542 claims |
| AmgenProlia | $214 | $21,61113 claims |
| AbbVieLinzess | $110 | $12,80116 claims |
| Johnson & JohnsonXarelto | $67 | $8,77522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in Jonesboro
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.